Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)

被引：0
|
作者：
Narendra, D. [1 ]
Baptist, A. P. [2 ]
Lee, L. [3 ]
Noorduyn, S. G. [4 ]
Liu, M. [5 ]
Igboekwe, E. E. [6 ]
Veeranki, P. [5 ]
Kahle-Wrobleski, K. [7 ]
Paczkowski, R. [3 ]
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI USA
[3] GSK, Value Evidence & Outcomes, Collegeville, PA USA
[4] GSK, Global Value Evidence & Outcomes, Mississauga, ON, Canada
[5] Optum, Hlth Econ & Outcomes Res, Minneapolis, MN USA
[6] GSK, US Med Affairs, Raleigh, NC USA
[7] GSK, US Med Affairs, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2091
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Sandeep Bansal
    Martin Anderson
    Antonio Anzueto
    Nicola Brown
    Chris Compton
    Thomas C. Corbridge
    David Erb
    Catherine Harvey
    Morrys C. Kaisermann
    Mitchell Kaye
    David A. Lipson
    Neil Martin
    Chang-Qing Zhu
    Alberto Papi
    npj Primary Care Respiratory Medicine, 31
  • [2] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Bansal, Sandeep
    Anderson, Martin
    Anzueto, Antonio
    Brown, Nicola
    Compton, Chris
    Corbridge, Thomas C.
    Erb, David
    Harvey, Catherine
    Kaisermann, Morrys C.
    Kaye, Mitchell
    Lipson, David A.
    Martin, Neil
    Zhu, Chang-Qing
    Papi, Alberto
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2021, 31 (01)
  • [3] Characterization of Patients with Asthma Initiating Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Wrobleski, Kristin
    Noorduyn, Stephen
    Lee, Lydia
    Igboekwe, Emmeline
    Liu, Meixia
    Veeranki, Phani
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB101 - AB101
  • [4] Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study
    Pavord, Ian
    Peachey, Guy
    Kerstjens, Huib
    Kerwin, Edward
    Nathan, Robert
    Hanania, Nicola
    Pascoe, Steven
    Fowler, Andrew
    Bailes, Zelie
    Edwards, Dawn
    Sule, Neal
    Barnes, Neil
    Boulet, Louis-Philippe
    Tabberer, Maggie
    Lee, Laurie
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB241 - AB241
  • [5] Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Meredith McCormack
    Rosirene Paczkowski
    Noelle N. Gronroos
    Stephen G. Noorduyn
    Lydia Lee
    Phani Veeranki
    Mary G. Johnson
    Emmeline Igboekwe
    Kristin Kahle-Wrobleski
    Reynold Panettieri
    Advances in Therapy, 2024, 41 : 1245 - 1261
  • [6] Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Mccormack, Meredith
    Paczkowski, Rosirene
    Gronroos, Noelle N.
    Noorduyn, Stephen G.
    Lee, Lydia
    Veeranki, Phani
    Johnson, Mary G.
    Igboekwe, Emmeline
    Kahle-Wrobleski, Kristin
    Panettieri, Reynold
    ADVANCES IN THERAPY, 2024, 41 (03) : 1245 - 1261
  • [7] Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study
    Pavord, Ian
    Peachey, Guy
    Kerstjens, Huib
    Kerwin, Edward
    Nathan, Robert
    Hanania, Nicola A.
    Pascoe, Steven
    Fowler, Andrew
    Bailes, Zelie
    Edwards, Dawn
    Sule, Neal
    Barnes, Neil
    Boulet, Louis-Philippe
    Tabberer, Maggie
    Lee, Laurie A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (06) : 459 - 460
  • [8] An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD
    Wells, J. M.
    Bhatt, S. P.
    Carr, T. F.
    Criner, G. J.
    Halpin, D. M. G.
    Han, M. K.
    Jain, R.
    Kaye, M. G.
    Kraft, M.
    Lipson, D. A.
    Mapel, D.
    Mammen, M. J.
    McEvoy, C.
    Midwinter, D.
    Singh, D.
    Wise, R.
    Dransfield, M. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [9] Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
    Mannino, David
    Bogart, Michael
    Germain, Guillaume
    Huang, Shirley P.
    Ismaila, Afisi S.
    Laliberte, Francois
    Jung, Young
    MacKnight, Sean D.
    Stiegler, Marjorie A.
    Duh, Mei Sheng
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 491 - 504
  • [10] Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC plus FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials
    Hanania, Nicola A.
    Caveney, Scott
    Soule, Tedi
    Tombs, Lee
    Lettis, Sally
    Crim, Courtney
    Mannino, David M.
    Patel, Hitesh
    Boucot, Isabelle H.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 1925 - 1938
12345